Gossamer Bio Inc (GOSS)
0.80
-0.02
(-2.44%)
USD |
NASDAQ |
Apr 18, 16:00
0.7972
0.00 (0.00%)
After-Hours: 20:00
Gossamer Bio Cash from Financing (TTM): 190.15M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 190.15M |
September 30, 2023 | 190.18M |
June 30, 2023 | 110.91M |
March 31, 2023 | 113.83M |
December 31, 2022 | 117.09M |
September 30, 2022 | 120.33M |
June 30, 2022 | 3.026M |
March 31, 2022 | 3.276M |
December 31, 2021 | 3.329M |
September 30, 2021 | 3.207M |
June 30, 2021 | 2.185M |
Date | Value |
---|---|
March 31, 2021 | 312.74M |
December 31, 2020 | 312.54M |
September 30, 2020 | 313.81M |
June 30, 2020 | 313.29M |
March 31, 2020 | 30.80M |
December 31, 2019 | 321.58M |
September 30, 2019 | 317.92M |
June 30, 2019 | 547.10M |
March 31, 2019 | 520.30M |
December 31, 2018 | 300.86M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.185M
Minimum
Jun 2021
547.10M
Maximum
Jun 2019
175.12M
Average
120.33M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Amicus Therapeutics Inc | 61.68M |
TG Therapeutics Inc | 72.70M |
Replimune Group Inc | 16.34M |
89bio Inc | 513.11M |
Moderna Inc | -1.377B |